"Urgent care offered in Metairie, LA, Sacramento, CA & Austin, TX"

During the past decade, Benchmark Research conducted 54 clinical trials. In the 10-year time frame, 54 clinical trials started and 45 clinical trials were completed, i.e. on average, 83.3% percent of trials that started reached the finish line to date. In the past 5 years, 33 clinical trials started and 24 clinical trials were completed. i.e. 72.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Benchmark Research" #1 sponsor was "Pfizer" with 25 trials, followed by "ModernaTX, Inc." with 12 trials sponsored, "MedImmune LLC" with 6 trials sponsored, "Protein Sciences Corporation" with 5 trials sponsored and "BioNTech SE" with 5 trials sponsored. Other sponsors include 45 different institutions and companies that sponsored additional 43 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Benchmark Research" #1 collaborator was "Biomedical Advanced Research and Development Authority" with 5 trials as a collaborator, "Department of Health and Human Services" with 4 trials as a collaborator, "Pfizer" with 4 trials as a collaborator, "Integrium" with 1 trials as a collaborator and "National Institute of Allergy and Infectious Diseases (NIAID)" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Benchmark Research" are "Influenza" (16 trials), "COVID-19" (7 trials), "SARS-CoV-2" (7 trials), "SARS-CoV-2 Infection" (7 trials) and "Pneumococcal Disease" (4 trials). Many other conditions were trialed in "Benchmark Research" in a lesser frequency.

Most popular intervention types in "Benchmark Research" are "Biological" (71 trials), "Drug" (28 trials), "Other" (18 trials), "Device" (3 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (42 trials), "Saline" (5 trials), "mRNA-1273" (5 trials), "BNT162b2" (4 trials) and "rLP2086" (4 trials). Other intervention names were less common.

The vast majority of trials in "Benchmark Research" are 97 trials for "All" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "Benchmark Research". undefined are not yet recruiting, 4 are recruiting, 11 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 81 completed trials in Benchmark Research, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Benchmark Research, 13 "Phase 1" clinical trials were conducted, 39 "Phase 2" clinical trials and 53 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 2 trials that are defined as “Not Applicable".